Skip to content

Study · Animal study (in vivo) · rat · 2010

3 results

Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of gonadotrophin-releasing hormone (GnRH), its analogues and melatonin.

Boczek-Leszczyk E, Stempniak B, Juszczak M

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society1 Aug 2010Cited by 9 (Europe PMC)

PMID20814074 (opens in a new tab)PepBankPUB-20814074
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In rats, histrelin infusion increased plasma vasopressin compared with controls.

    In plain wordsIn rats, histrelin increased blood vasopressin compared with controls.

    Peptide
    Histrelin
    Outcome
    IncreasePlasma vasopressin
    Study

    ratn: not reported in source

    Comparator
    Control animals
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    After intracerebroventricular (i.c.v.) infusion of native GnRH or its agonist, blood plasma VP concentration was significantly higher than in control animals, which was accompanied by decreased content of the hormone in the neurohypophysis.
    1 context sentence
    Summary · context
    In this study we demonstrate, for the first time, that the highly selective GnRH agonist (i.e., [Des-Gly(10),D-His(Bzl)(6),Pro-NHEt(9)]-LHRH; histrelin) stimulates the release of VP from the rat H-N system, while native GnRH and its antagonist remain inactive in modifying this process in vitro.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In rats, histrelin infusion decreased neurohypophysial vasopressin content compared with controls.

    In plain wordsIn rats, histrelin decreased vasopressin stored in the neurohypophysis compared with controls.

    Peptide
    Histrelin
    Outcome
    DecreaseNeurohypophysial vasopressin content
    Study

    ratn: not reported in source

    Comparator
    Control animals
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (rat).

    Source sentences

    Summary
    After intracerebroventricular (i.c.v.) infusion of native GnRH or its agonist, blood plasma VP concentration was significantly higher than in control animals, which was accompanied by decreased content of the hormone in the neurohypophysis.
    1 context sentence
    Summary · context
    In this study we demonstrate, for the first time, that the highly selective GnRH agonist (i.e., [Des-Gly(10),D-His(Bzl)(6),Pro-NHEt(9)]-LHRH; histrelin) stimulates the release of VP from the rat H-N system, while native GnRH and its antagonist remain inactive in modifying this process in vitro.
  3. 03LabEx vivo tissueActivity measurement

    In rat hypothalamo-neurohypophysial tissue, histrelin stimulated vasopressin release in vitro.

    In plain wordsIn lab tests, histrelin increased vasopressin release from rat tissue.

    Peptide
    Histrelin
    Outcome
    IncreaseVasopressin release
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study we demonstrate, for the first time, that the highly selective GnRH agonist (i.e., [Des-Gly(10),D-His(Bzl)(6),Pro-NHEt(9)]-LHRH; histrelin) stimulates the release of VP from the rat H-N system, while native GnRH and its antagonist remain inactive in modifying this process in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.